WS #2591

The geopolitical de-escalation narrative from the previous synthesis is now STABLE, with President Trump's 5-day halt on strikes against Iranian power plants confirmed and markets rebounding as oil tumbles. However, this relief is tempered by emerging second-order inflationary pressures: fertilizer prices have surged to their highest level since September 2022 due to Strait of Hormuz disruptions, threatening near-term food price increases. This creates a complex macro backdrop where energy market relief could be offset by broader commodity inflation. Fed commentary remains the dominant market theme, with Fed official Miran providing contradictory signals—initially dovish on rate cuts and oil shock impacts, but later warning that second-round effects and wage rises could require rate hikes. This mixed messaging introduces uncertainty about the Fed's path, potentially dampening the bullish momentum from geopolitical de-escalation. Corporate developments show mixed sentiment with Apogee Therapeutics surging on clinical trial data while Nutanix faces a downgrade, and regulatory scrutiny emerges around the Paramount-Warner Bros. Discovery deal.